JP2021500905A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500905A5 JP2021500905A5 JP2020524042A JP2020524042A JP2021500905A5 JP 2021500905 A5 JP2021500905 A5 JP 2021500905A5 JP 2020524042 A JP2020524042 A JP 2020524042A JP 2020524042 A JP2020524042 A JP 2020524042A JP 2021500905 A5 JP2021500905 A5 JP 2021500905A5
- Authority
- JP
- Japan
- Prior art keywords
- marker
- cell
- kit
- marker component
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003550 marker Substances 0.000 claims description 104
- 210000004027 cell Anatomy 0.000 claims description 89
- 239000013598 vector Substances 0.000 claims description 34
- 239000003153 chemical reaction reagent Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 230000014509 gene expression Effects 0.000 claims description 12
- 150000007523 nucleic acids Chemical group 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 6
- 239000011324 bead Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000002463 transducing effect Effects 0.000 claims description 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 230000009261 transgenic effect Effects 0.000 claims description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1718088.6 | 2017-11-01 | ||
| GBGB1718088.6A GB201718088D0 (en) | 2017-11-01 | 2017-11-01 | Vectors |
| PCT/GB2018/053149 WO2019086865A1 (en) | 2017-11-01 | 2018-10-31 | Vectors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021500905A JP2021500905A (ja) | 2021-01-14 |
| JP2021500905A5 true JP2021500905A5 (enExample) | 2021-10-14 |
Family
ID=60580018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524042A Pending JP2021500905A (ja) | 2017-11-01 | 2018-10-31 | ベクター |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210214748A1 (enExample) |
| EP (1) | EP3703713A1 (enExample) |
| JP (1) | JP2021500905A (enExample) |
| KR (1) | KR20200083554A (enExample) |
| CN (1) | CN111278982A (enExample) |
| AU (1) | AU2018361810A1 (enExample) |
| BR (1) | BR112020008771A2 (enExample) |
| CA (1) | CA3080299A1 (enExample) |
| CL (1) | CL2020001135A1 (enExample) |
| GB (1) | GB201718088D0 (enExample) |
| IL (1) | IL274278A (enExample) |
| MX (1) | MX2020007225A (enExample) |
| RU (1) | RU2020117772A (enExample) |
| SG (1) | SG11202003682SA (enExample) |
| WO (1) | WO2019086865A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| CN119661722A (zh) | 2019-02-21 | 2025-03-21 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| EP3927747A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| GB2609554B (en) | 2020-01-03 | 2025-08-20 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| CN115975945B (zh) * | 2022-10-25 | 2025-10-28 | 苏州大学 | 荧光蛋白mKate2特异性标记的细胞外囊泡及其构建方法及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE251181T1 (de) * | 1998-07-28 | 2003-10-15 | Micromet Ag | Heterominikörper |
| US8771988B2 (en) * | 2007-10-12 | 2014-07-08 | Hoffmann-La Roche Inc. | Protein expression from multiple nucleic acids |
| GB201501936D0 (en) * | 2015-02-05 | 2015-03-25 | Ucl Business Plc | Signalling system |
| AU2016342041B2 (en) * | 2015-10-23 | 2021-12-02 | Eureka Therapeutics, Inc. | Antibody/T-cell receptor chimeric constructs and uses thereof |
-
2017
- 2017-11-01 GB GBGB1718088.6A patent/GB201718088D0/en not_active Ceased
-
2018
- 2018-10-31 SG SG11202003682SA patent/SG11202003682SA/en unknown
- 2018-10-31 US US16/760,848 patent/US20210214748A1/en not_active Abandoned
- 2018-10-31 JP JP2020524042A patent/JP2021500905A/ja active Pending
- 2018-10-31 CA CA3080299A patent/CA3080299A1/en not_active Abandoned
- 2018-10-31 RU RU2020117772A patent/RU2020117772A/ru unknown
- 2018-10-31 WO PCT/GB2018/053149 patent/WO2019086865A1/en not_active Ceased
- 2018-10-31 AU AU2018361810A patent/AU2018361810A1/en not_active Abandoned
- 2018-10-31 EP EP18800281.0A patent/EP3703713A1/en not_active Withdrawn
- 2018-10-31 CN CN201880070714.6A patent/CN111278982A/zh active Pending
- 2018-10-31 KR KR1020207015705A patent/KR20200083554A/ko not_active Withdrawn
- 2018-10-31 MX MX2020007225A patent/MX2020007225A/es unknown
- 2018-10-31 BR BR112020008771-8A patent/BR112020008771A2/pt not_active Application Discontinuation
-
2020
- 2020-04-27 IL IL274278A patent/IL274278A/en unknown
- 2020-04-29 CL CL2020001135A patent/CL2020001135A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500905A5 (enExample) | ||
| Yun et al. | Human plasmacytoid dendritic cells mount a distinct antiviral response to virus-infected cells | |
| Legut et al. | A genome-scale screen for synthetic drivers of T cell proliferation | |
| Locatelli et al. | NK cells mediate a crucial graft-versus-leukemia effect in haploidentical-HSCT to cure high-risk acute leukemia | |
| Grassmann et al. | Early emergence of T central memory precursors programs clonal dominance during chronic viral infection | |
| Forconi et al. | A new hope for CD56negCD16pos NK cells as unconventional cytotoxic mediators: An adaptation to chronic diseases | |
| Eagle et al. | ULBP6/RAET1L is an additional human NKG2D ligand | |
| JP2021176313A (ja) | 単一細胞の大規模並行コンビナトリアル分析のためのシステム及び方法 | |
| RU2020117772A (ru) | Векторы | |
| Fuchs et al. | Gene expression-based identification of antigen-responsive CD8+ T cells on a single-cell level | |
| US11718929B2 (en) | Methods for making novel antigen binding domains | |
| Reynaud et al. | Gene profiling of CD11b+ and CD11b− B1 cell subsets reveals potential cell sorting artifacts | |
| KR20220078611A (ko) | 일차 인간 세포에서 동족 t 세포 및 에피토프 반응성을 스크리닝하기 위한 고처리량 방법 | |
| CN105131126B (zh) | 用于治疗恶性肿瘤的嵌合抗原受体及其制备方法与应用 | |
| Lin et al. | Human NK cells licensed by killer Ig receptor genes have an altered cytokine program that modifies CD4+ T cell function | |
| Mbiribindi et al. | Epstein–Barr virus peptides derived from latent cycle proteins alter NKG2A+ NK cell effector function | |
| Sumida et al. | G-protein coupled receptor 18 contributes to establishment of the CD8 effector T cell compartment | |
| Toffoli et al. | Enhancement of NK cell antitumor effector functions using a bispecific single domain antibody targeting CD16 and the epidermal growth factor receptor | |
| TWI814745B (zh) | 使用效應T細胞(Teff)抗原受體之抗原特異性控制性T細胞(Treg)之製出技術 | |
| Makanga et al. | Genetic and molecular basis of heterogeneous NK cell responses against acute leukemia | |
| Hurtado et al. | Efficient isolation of rare B cells using next-generation antigen barcoding | |
| Sundbäck et al. | Cloning of minimally divergent allelic forms of the natural killer (NK) receptor Ly-49C, differentially controlled by host genes in the MHC and NK gene complexes. | |
| CN115835873A (zh) | 用于产生表达重组受体的供体分批细胞的方法 | |
| Beura et al. | Novel lymphocytic choriomeningitis virus strain sustains abundant exhausted progenitor CD8 T cells without systemic viremia | |
| Andrews et al. | Generation of antiviral major histocompatibility complex class I-restricted T cells in the absence of CD8 coreceptors |